The serotonergic system in motor and non-motor manifestations of Parkinson's disease

P Huot, SH Fox - Experimental brain research, 2013 - Springer
The understanding of Parkinson's disease (PD) classically revolves around dopamine
depletion within the striatum. However, PD is a multi-systemic disease in which extra …

New insight into the therapeutic role of the serotonergic system in Parkinson's disease

Y Ohno, S Shimizu, K Tokudome, N Kunisawa… - Progress in …, 2015 - Elsevier
Parkinson's disease (PD) is a common, late-onset neurodegenerative disorder that shows
progressive extrapyramidal motor disorders (eg, bradykinesia, resting tremors, muscle …

The serotonergic system in Parkinson's disease

P Huot, SH Fox, JM Brotchie - Progress in neurobiology, 2011 - Elsevier
Although the cardinal manifestations of Parkinson's disease (PD) are attributed to a decline
in dopamine levels in the striatum, a breadth of non-motor features and treatment-related …

Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study

M Politis, K Wu, C Loane, L Kiferle, S Molloy… - Neurobiology of …, 2010 - Elsevier
Thirty Parkinson's disease (PD) patients were divided into three equal groups according to
their disease duration while 10 normal healthy volunteers matched for age and sex served …

Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating …

P Huot, SH Fox, A Newman-Tancredi… - Journal of Pharmacology …, 2011 - ASPET
l-DOPA remains the most effective treatment for Parkinson's disease (PD). However, long-
term administration of l-DOPA is compromised by complications, particularly dyskinesia …

Serotonergic approaches in Parkinson's disease: translational perspectives, an update

P Huot, V Sgambato-Faure, SH Fox… - ACS Chemical …, 2017 - ACS Publications
Parkinson's disease (PD) has long been seen as a disorder caused by degeneration of the
dopaminergic system, leading to the classic motor manifestations of the disease. However …

Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease

SJ Kish, J Tong, O Hornykiewicz, A Rajput, LJ Chang… - Brain, 2008 - academic.oup.com
Interest in serotonergic involvement in Parkinson's disease (PD) has focussed recently on
the possibility that the remaining serotonin neurons innervating striatum (caudate and …

Pathophysiological roles of serotonergic system in regulating extrapyramidal motor functions

Y Ohno, S Shimizu, K Tokudome - Biological and Pharmaceutical …, 2013 - jstage.jst.go.jp
The serotonergic nervous system plays crucial roles in regulating psycho-emotional,
cognitive, sensori-motor and autonomic functions. It is now known that multiple serotonin (5 …

[HTML][HTML] Improving the treatment of Parkinson's disease: A novel approach by modulating 5-HT1A receptors

S Shimizu, Y Ohno - Aging and disease, 2013 - ncbi.nlm.nih.gov
Parkinson's disease, the most common neurological disorder in the elderly, is characterized
by progressive extrapyramidal motor dysfunction including resting tremors, muscle rigidity …

5‐hydroxytryptamine (5‐HT, serotonin) and Parkinson's disease–opportunities for novel therapeutics to reduce the problems of levodopa therapy

SL Nicholson, JM Brotchie - European Journal of Neurology, 2002 - Wiley Online Library
While Parkinson's disease is undoubtedly a disorder with a primary pathology of dopamine
neuronal loss, that loss of dopamine and subsequent dopamine replacement therapy leads …